Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement covers exclusive commercialization rights to CRB-701, a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: CRB-701
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Corbus Pharmaceuticals
Deal Size: $692.5 million Upfront Cash: $7.5 million
Deal Type: Licensing Agreement February 13, 2023